HEPA
Hepion Pharmaceuticals, Inc. (HEPA) ESG Analysis Analysis (2026)
No material changes this month.
Environmental
No disclosed emissions, energy, or waste metrics in the provided filings data limits peer comparison, leaving environmental positioning broadly opaque versus peers.
Zero reported R&D intensity suggests limited disclosure on process innovation, which weakens evidence of environmental efficiency relative to better-disclosing peers.
The absence of capital-allocation detail tied to environmental initiatives reduces visibility into transition preparedness, unlike peers with clearer sustainability investment reporting.
Limited environmental reporting constrains assessment of regulatory exposure and operational footprint, keeping the company near the peer median rather than advantaged.
Social
No workforce, safety, turnover, or diversity metrics were provided, so social positioning cannot be shown as stronger than peers with fuller disclosure.
The lack of disclosed human-capital indicators reduces transparency on labor practices, which is a disadvantage versus peers that report more complete social KPIs.
No customer, product-safety, or community-impact metrics were supplied, limiting evidence of differentiated social risk management relative to peers.
Overall social disclosure appears incomplete, leaving the company positioned around the peer average rather than clearly above it.
Governance
Zero stock-based compensation to revenue suggests limited dilution pressure, which is a modest governance strength versus peers with heavier equity compensation.
Net debt to EBITDA of 0.57 indicates restrained leverage, supporting governance discipline relative to more highly levered peers.
However, the absence of board, audit, and ownership disclosures prevents a stronger governance assessment, keeping the profile only moderately above peers.
Overall governance appears somewhat disciplined on capital structure, but incomplete disclosure limits evidence of a materially superior control environment.
Overall Score
HEPA’s ESG positioning is broadly average versus peers because limited disclosure offsets modest governance discipline and leaves environmental and social assessment incomplete.
Score Driver: Incomplete ESG Disclosure Across Environmental And Social Dimensions
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Hepion Pharmaceuticals, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.